{"commentary":{"count":240,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":120,"youtube":67,"podcast":47,"x_video":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05740566\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DeLLphi-304","nct_id":"NCT05740566","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-304-nct05740566. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DeLLphi-304","arms":[{"description":"Participants will receive tarlatamab as an intravenous (IV) infusion.","label":"Tarlatamab","type":"EXPERIMENTAL"},{"description":"Participants will receive treatment per local standard of care (SOC).","label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-03-26","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":{"count":509,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tarlatamab","type":"DRUG"},{"name":"Lurbinectedin","type":"DRUG"},{"name":"Topotecan","type":"DRUG"},{"name":"Amrubicin","type":"DRUG"}],"last_update":"2026-01-05","lead_sponsor":"Amgen","official_title":"A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-01-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months"}],"references":[{"citation":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gumus M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazieres J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025 Jul 24;393(4):349-361. doi: 10.1056/NEJMoa2502099. Epub 2025 Jun 2.","pmid":"40454646","type":"BACKGROUND"},{"citation":"Dirnberger F, Patel S, Boyne DJ, Lan Z, Uyei J, Wang J, Cho S, DeCosta L, Bridges IM, Tapan U. Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer. Adv Ther. 2026 Sep;43(9):4282-4298. doi: 10.1007/s12325-026-03659-4. Epub 2026 Jun 30.","pmid":"42377743","type":"DERIVED"},{"citation":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. Future Oncol. 2024 Dec;20(40):3355-3364. doi: 10.1080/14796694.2024.2402152. Epub 2024 Nov 12.","pmid":"39530627","type":"DERIVED"}],"start_date":{"date":"2023-05-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05740566"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-304-nct05740566"}